Ermenegildo Zegna NV
ZGN
DexCom
DXCM
New Fortress Energy
NFE
Workday
WDAY
eBay
EBAY
US Stock MarketDetailed Quotes
APTO Aptose Biosciences
- 0.2790
- +0.1088+63.92%
Close Dec 20 16:00 ET
- 0.2250
- -0.0540-19.35%
Post 20:01 ET
16.61MMarket Cap-0.10P/E (TTM)
0.3895High0.2106Low306.25MVolume0.2700Open0.1702Pre Close94.96MTurnover543.67%Turnover RatioLossP/E (Static)59.52MShares2.680052wk High-1.82P/B15.72MFloat Cap0.130052wk Low--Dividend TTM56.33MShs Float1457.9988Historical High--Div YieldTTM105.11%Amplitude0.1300Historical Low0.3100Avg Price1Lot Size
Aptose Biosciences Stock Forum
Factors Influencing a Potential Rebound:
1. Clinical Developments:
• Tuspetinib Progress: Aptose’s lead compound, tuspetinib, has shown promise in treating acute myeloid leukemia (AML). Recent preclinical data demonstrate its unique mechanism of action and potential effectiveness, especially when combined with venetoclax.
2. Financi...
Aptose Biosciences Inc. has announced the publication of preclinical data in the Cancer Research Communications journal, detailing the unique mechanism of action of their lead compound, tuspetinib (TUS), and its potential in treating acute myeloid leukemia (AML).
Key Findings:
• Selective Kinase Inhibition: Tuspetinib targets specific oncogenic kinases associated with AML, including SYK, JAK1/2, RSK2, mutant KIT, and both wild-type and mutant forms of FL...
No comment yet